Foghorn Therapeutics (FHTX) EBT Margin (2020 - 2026)
Foghorn Therapeutics (FHTX) recorded quarterly EBT Margin of 607.01% in Q1 2026, down 153.23% quarter-over-quarter from 239.71% in Q4 2025, and down 26727.0% on a YoY basis from N/an in Q1 2025.
Foghorn Therapeutics (FHTX) EBT Margin (2020 - 2026) Analysis & Trends
Foghorn Therapeutics' EBT Margin history runs 7 years deep, the most recent figure standing at 607.01% for Q1 2026.
- In Q1 2026, EBT Margin fell 26727.0% year-over-year to 607.01%; the TTM figure through Mar 2026 stood at 273.72% (up 7441.0% YoY), while the FY2025 annual figure was 251.2%, up 13204.0% from the prior year.
- EBT Margin was 607.01% for Q1 2026 at Foghorn Therapeutics, down from 239.71% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 77.85% in Q3 2023 to a low of 690.39% in Q4 2022.
- Historically, EBT Margin has averaged 429.55% across 5 years, with a median of 388.44% in 2022.
- The sharpest annual moves came in 2022 and 2024: EBT Margin surged 6487985 bps in 2022, then plunged 29945 bps in 2024.
- A 5-year view of EBT Margin shows it stood at 690.39% in 2022, then jumped by 44 bps to 383.43% in 2023, then plunged by 78 bps to 682.88% in 2024, then surged by 65 bps to 239.71% in 2025, then slumped by 153 bps to 607.01% in 2026.
- The last three EBT Margin figures came in at 607.01% (Q1 2026), 239.71% (Q4 2025), and 202.0% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Foghorn Therapeutics | 282.33 Mn | 193.42 Mn | - | -607.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -607.01% |
| Dec 31, 2025 | -239.71% |
| Sep 30, 2025 | -202.00% |
| Jun 30, 2025 | -248.62% |
| Mar 31, 2025 | -339.73% |
| Dec 31, 2024 | -682.88% |
| Sep 30, 2024 | -244.90% |
| Jun 30, 2024 | -333.61% |
| Mar 31, 2024 | -495.37% |
| Dec 31, 2023 | -383.43% |
| Sep 30, 2023 | -77.85% |
| Jun 30, 2023 | -509.82% |
| Mar 31, 2023 | -563.72% |
| Dec 31, 2022 | -690.39% |
| Sep 30, 2022 | -388.44% |
| Jun 30, 2022 | -608.31% |
| Mar 31, 2022 | -686.58% |
| Dec 31, 2021 | -3,998.32% |
| Sep 30, 2021 | -65,268.29% |
| Jun 30, 2021 | -8,514.70% |